Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies

Becklin, Kelsie L.; Draper, Garrett M.; Madden, Rebecca A; Kluesner, Mitchell G.; Koga, Tomoyuki; Huang, Miller; Weiss, William A.; Spector, Logan G.; Largaespada, David A.; Moriarity, Branden S.; Webber, Beau R.

doi:10.1089/crispr.2022.0032

Cited by 3 publications

(14 citation statements)

References 341 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, Parisian et al induced SMARCB1 knockdown during the differentiation of cerebral organoids and found that there is a narrow developmental window where SMARCB1 loss could take effect for the transformation of the neural lineage cells [150] . This suggests that organoid models are useful not only for preclinical testing but also for dissecting the tumor biology in the context of neural development, which will shed light on the research on pediatric brain tumors, especially embryonal tumors [151] .…”

Section: Modeling Medulloblastomas and Other Pediatric Brain Tumorsmentioning

confidence: 99%

Pioneering models of pediatric brain tumors

Grigore¹,

Yang²,

Chen³

et al. 2023

Neoplasia

Self Cite

View full text Add to dashboard Cite

Section: Modeling Medulloblastomas and Other Pediatric Brain Tumorsmentioning

confidence: 99%

Pioneering models of pediatric brain tumors

Grigore¹,

Yang²,

Chen³

et al. 2023

Neoplasia

Self Cite

View full text Add to dashboard Cite

“…Additionally, iPSCs can be utilized to produce immune cells with enhanced anti-tumor properties, facilitating the development of immunotherapies for cancer treatment. The versatility and adaptability of iPSCs make them a valuable tool in the development of innovative cancer therapies [ 555 , 606 ].…”

Section: Future Of Ipscs In Tumorigenesismentioning

confidence: 99%

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy

Chehelgerdi,

Behdarvand Dehkordi,

Chehelgerdi

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. The formation of cancer is a multifaceted process influenced by genetic, epigenetic, and environmental factors. iPSCs offer a distinctive platform for investigating the origin of cancer, paving the way for novel approaches to cancer treatment, drug testing, and tailored medical interventions. This review article will provide an overview of the science behind iPSCs, the current limitations and challenges in iPSC-based cancer therapy, the ethical and social implications, and the comparative analysis with other stem cell types for cancer treatment. The article will also discuss the applications of iPSCs in tumorigenesis, the future of iPSCs in tumorigenesis research, and highlight successful case studies utilizing iPSCs in tumorigenesis research. The conclusion will summarize the advancements made in iPSC-based tumorigenesis research and the importance of continued investment in iPSC research to unlock the full potential of these cells.

show abstract

“…Development of novel models of cancer predisposition syndromes with improved gene editing systems is underway. 39 One of the main benefits of improved CRISPR-Cas9 meditated gene editing is avoiding the induction of a DSB whenever possible. It has been shown that even intended on-target DSBs created by CRISPR-Cas9 can result in a variety of large scale chromosomal arrangements and extrachromosomal DNA.…”

Section: Summary and Future Perspectivesmentioning

confidence: 99%

“…There have been numerous uses of the CRISPR‐Cas system that deviate from the initially described programmable RNA guided DNA endonuclease system which initiates a double stranded DNA break. These original gene editing CRISPR‐Cas9 systems and subsequent derivatives such as base editors and prime editors and their potential uses in iPSC derived models of cancer are thoroughly reviewed in detail elsewhere 39–42 . Here we provide an up‐to‐date summary of several novel methods of large‐scale gene integration, additional improvements to prime editing, and how these gene editing technologies can be applied to improve human cell line models of cancer predisposition syndromes.…”

Section: Next‐generation Crispr Derived Precision Gene Editing Techno...mentioning

confidence: 99%

See 1 more Smart Citation

Modeling human cancer predisposition syndromes using CRISPR/Cas9 in human cell line models

Draper

Panken

Largaespada

2023

Genes Chromosomes & Cancer

Self Cite

View full text Add to dashboard Cite

The advancement of CRISPR mediated gene engineering provides an opportunity to improve upon preclinical human cell line models of cancer predisposing syndromes. This review focuses on using CRISPR/Cas9 genome editing tools to model various human cancer predisposition syndromes. We examine the genetic mutations associated with neurofibromatosis type 1, Li‐Fraumeni syndrome, Gorlin syndrome, BRCA mutant breast and ovarian cancers, and APC mutant cancers. Furthermore, we discuss the possibilities of using next‐generation CRISPR‐derived precision gene editing tools to introduce a variety of genetic lesions into human cell lines. The goal is to improve the quality of preclinical models surrounding these cancer predisposition syndromes through dissecting the effects of these mutations on the development of cancer and to provide new insights into the underlying mechanisms of these cancer predisposition syndromes. These studies demonstrate the continued utility and improvement of CRISPR/Cas9‐induced human cell line models in studying the genetic basis of cancer.

show abstract

Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies

Cited by 3 publications

References 341 publications

Pioneering models of pediatric brain tumors

Pioneering models of pediatric brain tumors

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy

Modeling human cancer predisposition syndromes using CRISPR/Cas9 in human cell line models

Contact Info

Product

Resources

About